Loading…
Loading…
POLBF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for POLBF and 80,000+ other tickers.
See exactly how POLBF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for POLBF and 80,000+ other tickers.
Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Kinase inhibitor being advanced for the treatment of severe influenza. POLB 002: An innovative, first-in-class RNA-based immunotherapy, acquired through a licensing agreement, designed for intranasal administration to combat various respiratory viral infections. POLB 003: An intramuscular vaccine aimed at preventing Melioidosis. Beyond specific drug candidates…
Poolbeg Pharma PLC (AIM:POLB) has secured a Notice of Allowance from the Israeli Patent Office for its POLB 001 cancer immunotherapy-induced cytokine release syndrome patent application. The clinical-stage biopharmaceutical company, which is focused on the cancer immunotherapy field, is developing POLB 001 as a potentially preventative oral therapy.
Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical, has raised £3.5 million before expenses through a share placing. Cathal Friel, executive chair, subscribed for £250,000 of the placing.
Cavendish has reiterated its 'buy' rating on Poolbeg Pharma PLC (AIM:POLB), arguing that the drug developer's first patient dosing marks the start of a value-creating period for the shares. The broker set a target price of 19p, implying upside of about 170% from the current 7.4p (up 5% on the day).
Poolbeg Pharma PLC (AIM:POLB), a clinical-stage biopharmaceutical company focused on cancer immunotherapy, has dosed the first patient in its POLB 001 TOPICAL clinical trial. The AIM-listed company is testing POLB 001 as a preventative treatment for cytokine release syndrome, a potentially serious immune reaction, in patients with relapsed or refractory multiple myeloma.
Poolbeg Pharma PLC (AIM:POLB), the biopharmaceutical company focused on cancer immunotherapy, said it had been granted a patent in South Africa for its lead drug candidate, POLB 001. The patent covers the use of POLB 001 in preventing severe influenza and hypercytokinaemia, an excessive immune response also known as a cytokine storm, and runs until December 2038.